IGF2BP2 and head and neck squamous cell carcinoma: Given the absence of public HNSCC CBP resistance datasets, we used the OncoPredict R package to stratify TCGA‐HNSCC patients, revealing that IGF2BP2, CDH2, and MAD1L1 were significantly upregulated (p < 0.01) in the CBP‐resistant group (top 25%) compared to the CBP‐sensitive group (bottom 25%) (Figure 3D).